Document is current

Article History

Received: 16 January 2023

Accepted: 6 March 2023

First Online: 23 March 2023

Declarations

:

: All patients provided written informed consent. The study was approved by IRCCS San Raffaele Rome Ethical Committee n RP 19/26, mutually recognized by the other local ethical committees.

: Piero Barbanti received travel grants, honoraria for advisory boards, speaker panels or clinical investigation studies from Alder, Allergan, Angelini, Assosalute, Bayer, ElectroCore, Eli-Lilly, GSK, Lundbeck, Lusofarmaco, 1MED, MSD, New Penta, Noema Pharma, Novartis, Stx-Med, Teva, Visufarma, Zambon.CinziaAurilia received travel grants from FB-Health, Lusofarmaco, Almirall, Eli-Lilly Novartis and Teva;Gabriella Egeo received travel grants and honoraria from Eli-Lilly, Novartis, New Penta and Ecupharma;Paola Torelli received travel grants and honoraria from Allergan, Teva, Eli-Lilly and Novartis.Cinzia Finocchi received grants and honoraria from Novartis, Eli Lilly, TEVA, AIM group.Florindo d'Onofrio received travel grant, honoraria as a speaker or for partecipating in advisory boards from Novartis, Teva, Neopharmed Gentili, Qbgroupsrl, K link srl and Eli-Lilly.Luigi d’Onofrio has no disclosures to declaire.Renata Rao received honoraria for speaker panels from Teva, Lilly, Novartis, Allergan, Lundbeck.Stefano Messina has no disclosures to declare.Laura Di Clemente has no disclosures to declare.Angelo Ranieri received speaker honoraria from Teva, Lilly.Massimo Autunno has no disclosures to declare.Giuliano Sette has no disclosures to declare.Bruno Colombohas received congress fee reimbursements from Teva and Novartis.Antonio Carnevalehas no disclosures to declare.Marco Aguggia received grants from Novartis and Lilly.Miriam Tasillo has no disclosures to declare.Francesco Zoredduhas no disclosures to declare.Fabio Frediani has received fees for participation on advisory boards, speaker honoraria or consulting activities from Angelini, Cristalfarma, Ecupharma, IBSA, Lundbeck, Novartis, PIAM, Teva.Massimo Filippi is Editor-in-Chief of the Journal of Neurology; received compensation for consulting services and/or speaking activities from Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA).C. Tomino has no disclosures to declare.S. Proiettihas no disclosures to declare.S. Bonassi has no disclosures to declare.